Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
65
Language
English
Published on
21/02/24
You may also be interested by these reports :
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...
05/12/25
On the back of promising operating results, which also prompted management to upgrade its guidance, our estimates reset higher. This is commendable, ...
05/12/25
We have incorporated the actual figures for the FY24/25 ending in June 2025. While the recurring EBIT was in line with our forecast (€44.2m vs ...
03/12/25
Despite challenges that have reduced our target price, Demant still presents a significant upside. The company is poised to benefit from: 1) new ...